Welcome to our dedicated page for Nrx Pharmaceuticals news (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on Nrx Pharmaceuticals stock.
NRx Pharmaceuticals, Inc. reports clinical, regulatory, manufacturing, and subsidiary developments for a biopharmaceutical business focused on neuroplastic therapies for depression, PTSD, suicidality, and related conditions. Company updates center on NRX-100 preservative-free ketamine, NRX-101 as a D-cycloserine/lurasidone fixed-dose combination, FDA communications, generic-drug and new-drug application pathways, and clinical work involving treatment-resistant depression and suicidality.
Recurring news also covers commercial manufacturing preparations, drug-shortage context for ketamine injection, robotic-enabled transcranial magnetic stimulation initiatives through NRx Defense Systems, and interventional psychiatry activity through HOPE Therapeutics. Additional company developments include partnerships involving digital monitoring tools, leadership appointments, and research programs serving military, first-responder, and broader behavioral-health settings.
On May 25, 2021, NeuroRx announced its successful merger with Big Rock Partners Acquisition Corp., resulting in the formation of NRx Pharmaceuticals, Inc. The new entity will trade on the Nasdaq under the symbol NRXP. The company plans to use the public capital to advance the development of two investigational drugs: ZYESAMI™ for COVID-19 related respiratory failure and NRX-101 for suicidal bipolar depression. Both drugs are currently in FDA-approved Phase 3 trials. NRx aims to seek Emergency Use Authorization for ZYESAMI™ in May 2021.